Outcome After Gastrectomy in Gastric Cancer Patients with Type 2 Diabetes
Overview
Affiliations
Aim: To evaluate the prognosis of type II diabetes mellitus (T2DM) after gastrectomy and related factors in gastric cancer patients.
Methods: 403 gastric cancer patients with T2DM were studied, who underwent gastrectomy between May 2003 and September 2009. A review of medical records and telephone interviews was performed in this cross-sectional study. The factors included in the statistical analysis were as follows: gender, age, type of surgery, preoperative body mass index (BMI), current BMI, BMI reduction ratio, preoperative insulin or oral diabetic medicine requirement, follow-up duration, and current state of diabetes. Assessment of diabetes status after surgery was classified into four categories according to the change in hypoglycemic agents after surgery and present status of T2DM: resolution, improvement, same, and worse.
Results: The mean follow-up duration was 33.7 mo (± 20.6 mo), preoperative BMI was 24.7 kg/m(2) (± 3.0 kg/m(2)), and BMI reduction ratio was 9.8% (± 8.6%). After surgery, T2DM was cured in 58 patients (15.1%) and was improved in 117 patients (30.4%). According to the type of surgery, the BMI reduction ratio was significantly higher in the total gastrectomy and Roux-en-Y reconstruction group [14.2% ± 9.2% vs 9.2% ± 7.7% (Billroth II group), P < 0.001] and significantly lower in the subtotal gastrectomy and Billroth I reconstruction group [7.6% ± 8.0%, 9.2% ± 7.7% (Billroth II group), P < 0.001]. The BMI reduction ratio, follow-up duration after surgery, type of surgery, extent of gastrectomy, and performance of duodenal bypass were significantly correlated to the course of T2DM (P < 0.05). The BMI reduction ratio was the most influential factor on T2DM status. In a subgroup analysis of patients with a BMI reduction ratio of 10% or less (n = 206), T2DM was cured in 15 (7.6%) patients and was improved in 57 (28.8%) patients after surgery, and only the duration of surgery was significantly correlated to T2DM status (P = 0.022).
Conclusion: The course of T2DM was significantly correlated to the BMI reduction ratio but not to the type of surgery without a significant change in BMI.
Pinho Costa M, Santos-Sousa H, Oliveira C, Amorim-Cruz F, Bouca R, Barbosa E Sci Rep. 2024; 14(1):23477.
PMID: 39379429 PMC: 11461857. DOI: 10.1038/s41598-024-72456-2.
Diabetes Mellitus and Gastric Cancer: Correlation and Potential Mechanisms.
Wang L, Zhang Z J Diabetes Res. 2023; 2023:4388437.
PMID: 38020199 PMC: 10653978. DOI: 10.1155/2023/4388437.
Factors associated with hypertension remission after gastrectomy for gastric cancer patients.
Kang B, Liu X, Cheng Y, Tao W, Peng D World J Gastrointest Surg. 2022; 14(8):743-753.
PMID: 36157372 PMC: 9453326. DOI: 10.4240/wjgs.v14.i8.743.
Seo S, Cho Y, Heo Y, Seo D, Ahn S, Hong S Medicine (Baltimore). 2022; 101(36):e30309.
PMID: 36086777 PMC: 10980430. DOI: 10.1097/MD.0000000000030309.
Oncometabolic surgery in gastric cancer patients with type 2 diabetes.
Choi Y, Yi J, Shin W, Heo Y Sci Rep. 2022; 12(1):11853.
PMID: 35831319 PMC: 9279435. DOI: 10.1038/s41598-022-15404-2.